

L14 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2003 ACS  
ACCESSION NUMBER: 1999:401026 CAPLUS  
DOCUMENT NUMBER: 131:35871

TITLE: Compositions containing an association of  
aspirin and an anti-Xa oligosaccharide and use  
of anti-Xa oligosaccharide optionally in combination  
with aspirin

INVENTOR(S): Cariou, Roger; Stiekema, Jacobus  
PATENT ASSIGNEE(S): Sanofi S. A., Neth.; Akzo Nobel N. V.  
SOURCE: Pat. Specif. (Aust.), 26 pp.  
CODEN: ALXXAP

DOCUMENT TYPE: Patent  
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
AU 698456	B2	19981029		
AU 9716319	A1	19980917	AU 1997-16319	19970314
BR 9701313	A	19981117	BR 1997-1313	19970317
PRIORITY APPLN. INFO.:			BR 1997-1313	19970317

L14 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2003 ACS  
ACCESSION NUMBER: 1999:185867 CAPLUS  
DOCUMENT NUMBER: 130:232247

TITLE: Efficacy of a synthetic pentasaccharide, a pure factor  
Xa inhibitor, as an antithrombotic agent. A pilot  
study in the setting of coronary angioplasty  
AUTHOR(S): Vuilleminot, Alain; Schiele, Francois; Meneveau,  
Nicolas; Claudel, Sophie; Donat, Francois; Fontecave,  
Sylvie; Cariou, Roger; Samama, Meyer Michel;  
CORPORATE SOURCE: Bassand, Jean-Pierre  
SOURCE: Service Cardiologie, Hopital Saint-Jacques, Besancon,  
F-25030, Fr.  
PUBLISHER: Thrombosis and Haemostasis (1999), 81(2), 214-220  
DOCUMENT TYPE: CODEN: THHADQ; ISSN: 0340-6245  
LANGUAGE: F. K. Schattauer Verlagsgesellschaft mbH  
REFERENCE COUNT: Journal  
English

39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 7 OF 14 MEDLINE  
ACCESSION NUMBER: 1999367040 MEDLINE  
DOCUMENT NUMBER: 99367040 PubMed ID: 10440428

TITLE: Clopidogrel-rt-PA-heparin combination in the treatment of  
acute myocardial infarction.

AUTHOR: Bassand J P; Cariou R; Grollier G; Kragten J;  
CORPORATE SOURCE: Wolf J E; Heyndrickx G R  
SOURCE: Centre Hospitalier, Besancon, France.  
SEMINARS IN THROMBOSIS AND HEMOSTASIS, (1999) 25 Suppl 2  
69-75.

PUB. COUNTRY: Journal code: 0431155. ISSN: 0094-6176.  
DOCUMENT TYPE: United States

LANGUAGE: (CLINICAL TRIAL)  
(CLINICAL TRIAL, PHASE III)  
FILE SEGMENT: Journal; Article; (JOURNAL ARTICLE)  
ENTRY MONTH: (MULTICENTER STUDY)  
ENTRY DATE: English

Priority Journals  
199912  
Entered STN: 20000113

Last Updated on STN: 20000113  
Entered Medline: 19991210

L14 ANSWER 8 OF 14 MEDLINE  
ACCESSION NUMBER: 1999367027 MEDLINE  
DOCUMENT NUMBER: 99367027 PubMed ID: 10440415  
TITLE: Single-dose pharmacodynamics of clopidogrel.  
AUTHOR: Thebault J J; Kieffer G; Cariou R  
CORPORATE SOURCE: Institut Aster, Hopital Cognacq-Jay, Paris, France.  
SOURCE: SEMINARS IN THROMBOSIS AND HEMOSTASIS, (1999) 25 Suppl 2  
3-8.  
Journal code: 0431155. ISSN: 0094-6176.  
PUB. COUNTRY: United States  
DOCUMENT TYPE: (CLINICAL TRIAL)  
(CLINICAL TRIAL, PHASE III)  
Journal; Article; (JOURNAL ARTICLE)  
(RANDOMIZED CONTROLLED TRIAL)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 199912  
ENTRY DATE: Entered STN: 20000113  
Last Updated on STN: 20000113  
Entered Medline: 19991210

L14 ANSWER 9 OF 14 MEDLINE  
ACCESSION NUMBER: 1999161757 MEDLINE  
DOCUMENT NUMBER: 99161757 PubMed ID: 10063994  
TITLE: Efficacy of a synthetic pentasaccharide, a pure factor Xa  
inhibitor, as an antithrombotic agent--a pilot study in the  
setting of coronary angioplasty.  
AUTHOR: Vuilleminot A; Schiele F; Meneveau N; Claudel S; Donat F;  
Fontecave S; Cariou R; Samama M M; Bassand J P  
CORPORATE SOURCE: Hopital Universitaire Saint-Jacques, Besancon, France.  
SOURCE: THROMBOSIS AND HAEMOSTASIS, (1999 Feb) 81 (2) 214-20.  
Journal code: 7608063. ISSN: 0340-6245.  
PUB. COUNTRY: GERMANY: Germany, Federal Republic of  
DOCUMENT TYPE: (CLINICAL TRIAL)  
(CLINICAL TRIAL, PHASE II)  
Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 199906  
ENTRY DATE: Entered STN: 19990618  
Last Updated on STN: 19990618  
Entered Medline: 19990604

L14 ANSWER 10 OF 14 SCISEARCH COPYRIGHT 2003 ISI (R)  
ACCESSION NUMBER: 1999:598593 SCISEARCH  
THE GENUINE ARTICLE: 220KG  
TITLE: Clopidogrel-rt-PA-heparin combination in the treatment of  
acute myocardial infarction  
AUTHOR: Bassand J P (Reprint); Cariou R; Grollier G;  
Kragten J; Wolf J E; Heyndrickx G R  
CORPORATE SOURCE: HOP UNIV ST JACQUES, SERV CARDIOL, 2 PL ST JACQUES,  
F-25030 BESANCON, FRANCE (Reprint); SANOFI RECH, F-34082  
MONTPELLIER, FRANCE; CHRU, CAEN, FRANCE; DE WEEVER HOSP,  
HEERLEN, NETHERLANDS; CHU BOCAGE, DIJON, FRANCE  
COUNTRY OF AUTHOR: FRANCE; NETHERLANDS  
SOURCE: SEMINARS IN THROMBOSIS AND HEMOSTASIS, (JUN 1999) Vol. 25,  
Supp. [2], pp. 69-75.  
Publisher: THIEME MEDICAL PUBL INC, 333 SEVENTH AVE, NEW  
YORK, NY 10001.  
ISSN: 0094-6176.  
DOCUMENT TYPE: Article; Journal

FILE SEGMENT: LIFE; CLIN  
LANGUAGE: English  
REFERENCE COUNT: 9  
\*ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS\*

L14 ANSWER 11 OF 14 SCISEARCH COPYRIGHT 2003 ISI (R)  
ACCESSION NUMBER: 1999:598582 SCISEARCH  
THE GENUINE ARTICLE: 220KG  
TITLE: Clopidogrel loading dose regimens: Kinetic profile of pharmacodynamic response in healthy subjects  
AUTHOR: Savcic M (Reprint); Hauert J; Bachmann F; Wyld P J; Geudelin B; Cariou R  
CORPORATE SOURCE: CHU VAUDOIS, DIV CARDIOL, DEPT MED INTERNE, CH-1011 LAUSANNE, SWITZERLAND (Reprint); CHU VAUDOIS, DEPT INTERNAL MED, DIV HEMATOL, CH-1011 LAUSANNE, SWITZERLAND; INVERESK CLIN RES, EDINBURGH, MIDLOTHIAN, SCOTLAND; SANOFI RECH, GENEVA, SWITZERLAND; SANOFI RECH, F-34082 MONTPELLIER, FRANCE  
COUNTRY OF AUTHOR: SWITZERLAND; SCOTLAND; FRANCE  
SOURCE: SEMINARS IN THROMBOSIS AND HEMOSTASIS, (JUN 1999) Vol. 25, Supp. [2], pp. 15-19.  
Publisher: THIEME MEDICAL PUBL INC, 333 SEVENTH AVE, NEW YORK, NY 10001.  
ISSN: 0094-6176.  
DOCUMENT TYPE: Article; Journal  
FILE SEGMENT: LIFE; CLIN  
LANGUAGE: English  
REFERENCE COUNT: 20  
\*ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS\*

L14 ANSWER 12 OF 14 SCISEARCH COPYRIGHT 2003 ISI (R)  
ACCESSION NUMBER: 1999:148338 SCISEARCH  
THE GENUINE ARTICLE: 166DP  
TITLE: Efficacy of a synthetic pentasaccharide, a pure factor Xa inhibitor, as an antithrombotic agent a pilot study in the setting of coronary angioplasty  
AUTHOR: Vuilleminot A; Schiele F; Meneveau N; Claudel S; Donat F; Fontecave S; Cariou R; Samama M M; Bassand J P (Reprint)  
CORPORATE SOURCE: HOP UNIV ST JACQUES, SERV CARDIOL, 2 PL ST JACQUES, F-25030 BESANCON, FRANCE (Reprint); HOP UNIV ST JACQUES, SERV CARDIOL, F-25030 BESANCON, FRANCE; SANOFI RECH, F-34082 MONTPELLIER, FRANCE; HOP HOTEL DIEU, PARIS, FRANCE  
COUNTRY OF AUTHOR: FRANCE  
SOURCE: THROMBOSIS AND HAEMOSTASIS, (FEB 1999) Vol. 81, No. 2, pp. 214-220.  
Publisher: F K SCHATTAUER VERLAG GMBH, P O BOX 10 45 45, LENZHALDE 3, D-70040 STUTTGART, GERMANY.  
ISSN: 0340-6245.  
DOCUMENT TYPE: Article; Journal  
FILE SEGMENT: LIFE  
LANGUAGE: English  
REFERENCE COUNT: 39  
\*ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS\*

L14 ANSWER 13 OF 14 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.  
ACCESSION NUMBER: 1999261382 EMBASE  
TITLE: Clopidogrel-rt-PA-heparin combination in the treatment of acute myocardial infarction.  
AUTHOR: Bassand J.-P.; Cariou R.; Grollier G.; Kragten J.; Wolf J.-E.; Heyndrickx G.R.  
CORPORATE SOURCE: J.-P. Bassand, Service de Cardiologie, Hopital Universitaire Saint-Jacques, 2 Place Saint-Jacques, 25030 Besancon, France

SOURCE:                   Seminars in Thrombosis and Hemostasis, (1999) 25/SUPPL. 2  
                           (69-75).  
                           Refs: 9  
                           ISSN: 0094-6176   CODEN: STHMBV  
 COUNTRY:                   United States  
 DOCUMENT TYPE:           Journal; Article  
 FILE SEGMENT:           018       Cardiovascular Diseases and Cardiovascular Surgery  
                           037       Drug Literature Index  
 LANGUAGE:                English  
 SUMMARY LANGUAGE:       English

L14 ANSWER 14 OF 14   EMBASE   COPYRIGHT 2003 ELSEVIER SCI. B.V.

ACCESSION NUMBER:       1999061305   EMBASE  
 TITLE:                   Efficacy of a synthetic pentasaccharide, a pure factor Xa  
                           inhibitor, as an antithrombotic agent - A pilot study in  
                           the setting of coronary angioplasty.  
 AUTHOR:                  Vuilleminot A.; Schiele F.; Meneveau N.; Claudel S.; Donat  
                           F.; Fontecave S.; Cariou R.; Samama M.M.; Bassand  
                           J.-P.  
 CORPORATE SOURCE:       Prof. J.-P. Bassand, Service de Cardiologie, Hopital  
                           Universitaire Saint-Jacques, 2 place Saint-Jacques, 25030  
                           Besancon, France. jean-pierre.bassand@ufc-chu.univ-  
                           fcomte.fr  
 SOURCE:                  Thrombosis and Haemostasis, (1999) 81/2 (214-220).  
                           Refs: 39  
                           ISSN: 0340-6245   CODEN: THHADQ  
 COUNTRY:                  Germany  
 DOCUMENT TYPE:           Journal; Article  
 FILE SEGMENT:           018       Cardiovascular Diseases and Cardiovascular Surgery  
                           025       Hematology  
                           030       Pharmacology  
                           037       Drug Literature Index  
                           038       Adverse Reactions Titles  
 LANGUAGE:                English  
 SUMMARY LANGUAGE:       English

=>

L51 ANSWER 121 OF 125 PCTFULL COPYRIGHT 2003 Univentio

DETD These compounds may be used alone or in combination with other diagnostic, anticoagulant, antiplatelet or fibrinolytic agents. For example adjunctive administration of inhibitors of the activity of Factor Xa with standard 0 heparin, low molecular weight heparin, direct thrombin inhibitors (i.e. hirudin), aspirin, fibrinogen receptor antagonists, streptokinase, urokinase and/or tissue plasminogen activator may result in greater antithrombotic or thrombolytic efficacy or efficiency. The compounds described. . . in a variety of animals such as primates 5 including humans, sheep, horses, cattle, pigs, dogs, rats and mice. Inhibition of factor Xa is useful not only in the anticoagulant therapy of individuals having thrombotic conditions but is useful whenever inhibition of blood coagulation. . . coagulation of stored whole blood and to prevent coagulation in other biological samples for testing or storage. Thus, any inhibitor of Factor Xa activity can be added to or contacted with any medium containing or suspected of containing Factor Xa and in which it is desired that blood coagulation be inhibited.

In addition to their use in anticoagulant therapy, inhibitors of Factor Xa activity may find utility in the treatment or prevention of other physiological conditions in which the generation of thrombin has been implicated. . its ability to regulate many different cell types through specific cleavage and activation of a cell surface thrombin receptor. Inhibition of factor Xa activity will effectively block thrombin generation and therefore neutralize any pathologic effects of thrombin on various cell types.

. patient suffering from, or subject to, a physiological condition which can be ameliorated by the administration of an inhibitor of the Factor Xa activity, for example conditions as hereinbefore described, which comprises the administration to the patient of a therapeutically effective amount of compound of. . . 1. Effective amount is meant to describe an amount of compound of the present invention effective in inhibiting the activity of Factor Xa and thus producing the desired therapeutic effect.

ACCESSION NUMBER: 1996040679 PCTFULL ED 20020514  
TITLE (ENGLISH): SUBSTITUTED (SULFINIC ACID, SULFONIC ACID, SULFONYLAMINO OR SULFINYLAMINO) N- [ (AMINOIMINOMETHYL) PHENYLALKYL] -AZAHETEROCYCLYLAMIDE COMPOUNDS  
TITLE (FRENCH): COMPOSES D' (ACIDE SULFINIQUE, ACIDE SULFONIQUE, SULFONYLAMINO OU SULFINYLAMINO) N- [ (AMINOIMINOMETHYL) PHENYLALKYL] -AZAHETEROCYCLYLAMIDE

DETD These compounds may be used alone or in combination with other diagnostic, anticoagulant, antiplatelet or fibrinolytic agents. For example adjunctive administration of factor Xa inhibitors with standard heparin, low molecular weight heparin, direct thrombin inhibitors (i.e. hirudin), aspirin, fibrinogen receptor antagonists, streptokinase, urokinase and/or tissue plasminogen activator may result in greater antithrombotic or thrombolytic efficacy or efficiency. The compounds described herein. . . complications in a variety of animals such as primates including humans, sheep, horses, cattle, pigs, dogs, rats and mice. Inhibition of factor Xa is useful not only in the anticoagulant therapy of individuals having thrombotic conditions but is useful whenever inhibition of blood coagulation. . . to prevent coagulation of stored whole blood and to prevent coagulation in other biological samples for testing or storage. Thus, any factor Xa inhibitor can be added to or contacted with any medium containing or suspected of containing factor Xa and in which it is desired that blood coagulation be inhibited.

In addition to their use in anticoagulant therapy, factor Xa inhibitors may find utility in the treatment or prevention of other diseases in which the generation of thrombin has been implicated as. . . its ability to regulate many different cell types through specific cleavage and activation of a cell surface thrombin receptor. Inhibition of factor Xa will effectively block thrombin generation and therefore neutralize any pathologic effects of thrombin on various cell types.

animal patient suffering from, or subject to, 1 0 conditions which can be ameliorated by the administration of an inhibitor of Factor Xa, for example conditions as hereinbefore described, which comprises the administration to the patient of an effective amount of compound of formula. . . formula 1. Effective amount is meant to describe an amount of compound of the present invention effective in 1 5 inhibiting Factor Xa and thus producing the desired therapeutic effect.

ACCESSION NUMBER: 1997024118 PCTFULL ED 20020514  
TITLE (ENGLISH): SUBSTITUTED N-[(AMINOIMINOMETHYL OR AMINOMETHYL)PHENYL]PROPYL AMIDES  
TITLE (FRENCH): N-[(AMINOIMINOMETHYLE OU AMINOMETHYLE)PHENYLE]PROPYLAMIDES A SUBSTITUTION  
INVENTOR(S): GUERTIN, Kevin, R.;  
KLEIN, Scott, I.;  
SPADA, Alfred, P.  
PATENT ASSIGNEE(S): RHONE-POULENC RORER PHARMACEUTICALS INC.;  
GUERTIN, Kevin, R.;  
KLEIN, Scott, I.;  
SPADA, Alfred, P.

INVENTOR(S) :

SUBSTITUTES

EWING, William, R.;  
BECKER, Michael, R.;  
PAULS, Henry, W.;  
CHENEY, Daniel, L.;  
MASON, Jonathan, Stephen;  
SPADA, Alfred, P.;

PATENT ASSIGNEE(S) :

CHOI-SLEDESKI, Yong, Mi  
RHONE-POULENC RORER PHARMACEUTICALS INC.;  
EWING, William, R.;  
BECKER, Michael, R.;  
PAULS, Henry, W.;  
CHENEY, Daniel, L.;  
MASON, Jonathan, Stephen;  
SPADA, Alfred, P.;

LANGUAGE OF PUBL.:

English

DOCUMENT TYPE:

Patent

PATENT INFORMATION:

NUMBER	KIND	DATE
--------	------	------

WO 9640679	A1	19961219
------------	----	----------

DESIGNATED STATES

W:

AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI  
GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG  
MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR  
TT UA UG US UZ VN KE LS MW SD SZ UG AM AZ BY KG KZ MD  
RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL  
PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

APPLICATION INFO.:

WO 1996-US9816 A 19960607

PRIORITY INFO.:

US 1995-8/481,02

LANGUAGE OF PUBL.:  
DOCUMENT TYPE:  
PATENT INFORMATION:

English  
Patent

NUMBER	KIND	DATE
-----		
WO 9724118	A1	19970710

DESIGNATED STATES  
W:

AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI  
GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD  
MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM  
TR TT UA UG US UZ VN KE LS MW SD SZ UG AM AZ BY KG KZ  
MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC  
NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

APPLICATION INFO.:  
PRIORITY INFO.:

WO 1996-US20770 A 19961223  
US 1996-60/009,485 19960102